Close



Feb 15, 2023 07:04AM
Feb 15, 2023 07:00AM
Jan 19, 2023 09:39AM
Jan 19, 2023 08:01AM
Jan 19, 2023 08:00AM
Nov 21, 2022 07:00AM
Sep 12, 2022 05:22AM Concert Pharma (CNCE) Reports Presentation of CTP-543 THRIVE-AA1 Phase 3 Data
Sep 10, 2022 05:30AM
Aug 22, 2022 07:10AM
Aug 22, 2022 07:05AM
Aug 4, 2022 07:00AM
Aug 1, 2022 07:00AM
Aug 1, 2022 07:00AM
Jun 7, 2022 07:01AM Concert Pharma (CNCE) Reports Publication of Phase 2 Dose‑Ranging Trial Results of CTP‑543
Jun 7, 2022 07:00AM
May 23, 2022 07:01AM
May 23, 2022 07:00AM
May 23, 2022 07:00AM
May 5, 2022 07:00AM
Mar 3, 2022 06:00AM
Jan 4, 2022 07:00AM Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Nov 9, 2021 07:00AM
Oct 25, 2021 07:00AM
Aug 31, 2021 07:00AM
Aug 5, 2021 07:00AM
Jul 1, 2021 07:12AM
Jul 1, 2021 07:00AM
May 27, 2021 07:00AM Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Feb 25, 2021 07:00AM
Nov 5, 2020 06:00AM
Nov 3, 2020 07:21AM
Nov 3, 2020 07:00AM
Oct 29, 2020 10:00AM
Oct 29, 2020 10:00AM
Oct 22, 2020 07:14AM Concert Pharma (CNCE) Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology
Oct 22, 2020 07:00AM
Oct 13, 2020 07:00AM
Aug 6, 2020 09:06AM
Aug 6, 2020 07:00AM
Jul 8, 2020 07:03AM
Jul 8, 2020 07:00AM
Jun 12, 2020 04:03PM Concert Pharma (CNCE) Announces Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata
Jun 12, 2020 04:01PM
Apr 30, 2020 07:22AM
Apr 30, 2020 07:00AM
Apr 1, 2020 07:01AM
Apr 1, 2020 07:00AM
Feb 27, 2020 07:00AM
Feb 24, 2020 07:00AM Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at the 2020 American Academy of Dermatology Annual Meeting
Jan 23, 2020 07:52AM

251,872 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All